Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy

NCT01159327 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

13

Enrollment

OTHER_GOV

Sponsor class

Stopped low enrolling participants

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Sorafenib

Sponsor

National Cancer Center, Korea

Collaborators

[object Object]